Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet serotonin in systemic sclerosis.

P S Klimiuk1, A Grennan, C Weinkove

  • 1Rheumatic Diseases Centre, University of Manchester, Hope Hospital, Salford.

Annals of the Rheumatic Diseases
|July 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanisms of chronicity?

Journal of back and musculoskeletal rehabilitation·2014
Same author

Debate: This Society believes that in the last 25 years of back pain research we have failed to see the wood for the trees - Chaired by C.G. Greenough.

Journal of back and musculoskeletal rehabilitation·2014
Same author

Gender variation of human spinal and paraspinal structures.

Clinical biomechanics (Bristol, Avon)·2013
Same author

Fenclofenac tolerance in the dyspeptic patient.

Proceedings of the Royal Society of Medicine·2010
Same author

Selective changes in multifidus dimensions in patients with chronic low back pain.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2010
Same author

Endothelial-dependent vasodilation is impaired in patients with systemic sclerosis, as assessed by low dose iontophoresis.

Clinical and experimental rheumatology·2003
Same journal

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Annals of the rheumatic diseases·2026
Same journal

Commentary on 'Assessing the performance of AI chatbots in answering patients common questions about low back pain'.

Annals of the rheumatic diseases·2026
Same journal

Response to Correspondence on 'Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial'.

Annals of the rheumatic diseases·2026
Same journal

Correspondence on 'Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial' by Hawkins et al.

Annals of the rheumatic diseases·2026
Same journal

Response to correspondence on 'Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis' by Kaundal et al.

Annals of the rheumatic diseases·2026
Same journal

Correspondence on 'Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis' by Kaundal et al.

Annals of the rheumatic diseases·2026
See all related articles

Patients with the CREST variant of systemic sclerosis show lower platelet serotonin levels, indicating potential platelet activation. Treatment with ketanserin normalized these levels in CREST patients.

Area of Science:

  • Rheumatology
  • Hematology
  • Pharmacology

Background:

  • Systemic sclerosis is a complex autoimmune disease.
  • Platelet activation is implicated in the pathogenesis of systemic sclerosis.
  • The CREST variant (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia) is a subtype of systemic sclerosis.

Purpose of the Study:

  • To investigate platelet serotonin concentrations in patients with systemic sclerosis, including the CREST variant and primary Raynaud's phenomenon.
  • To explore the effect of ketanserin, a serotonin antagonist, on platelet serotonin levels in CREST patients.

Main Methods:

  • Platelet serotonin concentrations were measured in 43 systemic sclerosis patients (including CREST variant), 11 primary Raynaud's phenomenon patients, and 38 healthy controls.

Related Experiment Videos

  • Patients with CREST underwent treatment with ketanserin.

    • Main Results:

    • Significantly lower platelet serotonin concentrations were observed in patients with the CREST variant compared to normal controls.
    • Patients with diffuse systemic sclerosis exhibited normal platelet serotonin concentrations.
    • Ketanserin treatment normalized platelet serotonin concentrations in CREST patients.

    Conclusions:

    • These findings suggest widespread platelet activation in systemic sclerosis, particularly in the CREST variant.
    • Serotonin may play a role in the pathophysiology of systemic sclerosis-associated platelet activation.
    • Ketanserin shows potential in modulating platelet activity in this patient population.